Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Mariana Trovao da Silva has a total of 11 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Unraveling the Intestinal Microbiota Conundrum in Allogeneic Hematopoietic Stem Cell Transplantation: Fingerprints, Clinical Implications and Future Directions

    by Alexandre Soares Ferreira Júnior, Bianca Fernanda Rodrigues da Silva, Jefferson Luiz da Silva, Mariana Trovão da Silva, João Victor Piccolo Feliciano, Iago Colturato, George Maurício Navarro Barros, Phillip Scheinberg, Nelson Jen An Chao, Gislane Lelis Vilela de Oliveira

    Intestinal dysbiosis represents a critical determinant of clinical outcomes in patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT). Distinct microbiota patterns represent potential prognostic biomarkers and therapeutic targets. However, the exponential growth in microbiota research and analytical complexity has created significant interpretive challenges for clinicians. This review provides a synthesis of current literature examining microbiota fingerprints and their clinical implications. We analyzed key studies evaluating the clinical implications of intestinal microbiota fingerprints in allo-HSCT. Additionally, we examined current therapeutic strategies for microbiota modulation and approaches for translating research findings into clinical practice. We identified three major microbiota fingerprints: (1) decreased intestinal microbiota diversity, (2) reduced abundance of short-chain fatty acid-producing bacteria, and (3) Enterococcus domination. These fingerprints are associated with critical clinical outcomes including overall survival, Graft-versus-host disease, transplant-related mortality, and infection-related complications. While fecal microbiota transplantation and dietary interventions appear promising, current studies suffer from limited sample sizes and lack standardized protocols. Despite significant advances in microbiota research, biological, methodological, and logistical challenges continue to hinder its clinical translation. Understanding microbiota fingerprints represents a promising avenue for improving allo-HSCT outcomes. However, successful clinical implementation requires standardized methodologies, mechanistic studies, and multi-center collaborations to translate research into actionable clinical tools.


  • Open Access

    Unraveling the Intestinal Microbiota Conundrum in Allogeneic Hematopoietic Stem Cell Transplantation: Fingerprints, Clinical Implications and Future Directions

    by Alexandre Soares Ferreira Junior, Bianca Fernanda Rodrigues da Silva, Jefferson Luiz da Silva, Mariana Trovao da Silva, Joao Victor Piccolo Feliciano, Iago Colturato, George Maurício Navarro Barros, Phillip Scheinberg, Nelson J. Chao, Gislane Lelis Vilela de Oliveira

    Intestinal microbiota dysbiosis represents a critical determinant of clinical outcomes in patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT), with distinct microbiota patterns serving as potential prognostic biomarkers and therapeutic targets. However, the exponential growth in microbiota research and analytical complexity have created significant interpretive challenges for clinicians. This review provides a synthesis of current literature examining microbiota fingerprints and their clinical implications. We analyzed key studies evaluating the clinical implications of intestinal microbiota fingerprints in allo-HSCT. Additionally, we examined current therapeutic strategies for microbiota modulation and approaches for translating research findings into clinical practice. We identified three major microbiota fingerprints: 1) decreased intestinal diversity, 2) reduced abundance of short-chain fatty acid-producing bacteria, and 3) Enterococcus domination. These fingerprints are associated with critical clinical outcomes including overall survival, graft-versus-host disease, transplant-related mortality, and infectious complications. While fecal microbiota transplantation and dietary interventions appear promising, current studies suffer from limited sample sizes and lack standardized protocols. Despite advances in microbiota research, biological, methodological, and logistical challenges continue to impede clinical translation. Understanding microbiota fingerprints represents a promising avenue for improving allo-HSCT outcomes. However, successful clinical implementation requires standardized methodologies, mechanistic studies, and multi-center collaborations to translate research into actionable clinical tools.